From Yahoo Finance: 2025-05-05 16:17:00

Vertex Pharmaceuticals fell short of Wall Street expectations for quarterly results due to lower sales of its cystic fibrosis drug Trikafta, causing shares to drop 2.5%. However, the company raised its revenue forecast, banking on newer CF drugs and acute pain drug Journavx for growth. Analysts are watching closely as Vertex needs to successfully launch Journavx. The company’s next-generation treatment, Alyftrek, was approved by the FDA in December, strengthening its position in the CF market. CF is a genetic disorder affecting salt and water movement in cells. Sales of Trikafta in the first quarter reached $2.53 billion, slightly below expectations. Vertex is making progress with its gene therapy Casgevy for a rare blood disorder, with 90 patients starting cell collection. The company projects 2025 revenue of $11.85 billion to $12 billion, up from previous estimates. Quarterly revenue increased 2.7% to $2.77 billion, missing analyst estimates, with an adjusted profit of $4.06 per share, below expectations of $4.32.



Read more at Yahoo Finance: Vertex misses quarterly results on weaker-than-expected sales for cystic fibrosis drug